Evidence map›Paper›PMID 34224045›Full record

ArticleAnnals of surgical oncology2021

Definition and Prediction of Early Recurrence and Mortality Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: Towards Predicting Oncologic Futility Preoperatively.

Caroline J Rieser, Heather Jones, Lauren B Hall, Eliza Kang, Shannon Altpeter, Amer H Zureikat, Matthew P Holtzman, Andrew Lee, Melanie Ongchin, James F Pingpank and 2 more

Open access · greenAbstract read
In one paragraph

Article in Annals of surgical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 11 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Caroline J RieserDivision of Surgical Oncology, Koch Regional Perfusion Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. riesercj2@upmc.edu.ORCID http://orcid.org/0000-0002-4947-6996
Heather JonesDivision of Surgical Oncology, Koch Regional Perfusion Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Lauren B HallDivision of Surgical Oncology, Koch Regional Perfusion Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Eliza KangDivision of Surgical Oncology, Koch Regional Perfusion Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Shannon AltpeterDivision of Surgical Oncology, Koch Regional Perfusion Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Amer H ZureikatDivision of Surgical Oncology, Koch Regional Perfusion Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Matthew P HoltzmanDivision of Surgical Oncology, Koch Regional Perfusion Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Andrew LeeDivision of Surgical Oncology, Koch Regional Perfusion Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Melanie OngchinDivision of Surgical Oncology, Koch Regional Perfusion Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
James F PingpankDivision of Surgical Oncology, Koch Regional Perfusion Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
M Haroon A ChoudryDivision of Surgical Oncology, Koch Regional Perfusion Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
David L BartlettAHN Cancer Institute, Allegheny Health Network, Pittsburgh, PA, USA.
University of Pittsburgh Medical Center · USAllegheny Health Network · US

Funding

Postdoctoral Research Training in Biotherapy of CancerT32CA113263 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Udai S Kammula · 2006 to 2026
$3.6M
NCI NIH HHS T32 CA113263NCI NIH HHS T32CA113263
6 · The paper itself

Abstract

introductionEarly recurrence (ER) is a significant challenge for patients with colorectal peritoneal metastases (CRPM) following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS HIPEC). Preoperative risk stratification for ER would improve preoperative decision making.

methodsWe conducted a retrospective study examining patients who underwent CRS HIPEC for CRPM from 2000 to 2018. Optimal definition of ER was determined via minimum p-value approach based on differentiation of post-recurrence survival. Risk factors for ER were assessed in a derivation cohort by uni- and multivariate logistic regression. A predictive score for ER was generated using preoperative variables and validated in an independent cohort.

results384 patients were analyzed, 316 (82%) had documented recurrence. Optimal length of post-operative RFS to distinguish ER (n = 144, 46%) vs. late recurrence (LR) (n = 172, 63%) was 8 mos (p<0.01). ER patients had shorter median OS post-CRS-HIPEC (13.6 vs. 39.4 mos, p<0.01). Preoperative BMI (OR 1.88), liver lesions (OR 1.89), progression on chemotherapy (OR 2.14), positive lymph nodes (OR 2.47) and PCI score (16-20: OR 1.7; >20: OR 4.37) were significant predictors of ER (all p<0.05). Using this model, patients were assigned risk scores from 0 to 9. Intermediate (scores 4-6) and high-risk patients (score 7-9) had observed rates of ER of 56% and 79% and overall 2-year survival rates of 27% and 0% respectively. The model showed fair discrimination (AUC 0.72) and good calibration (Hosmer-Lemeshow GOF p = 0.68).

conclusionsER predicts markedly worse OS following surgery. Preoperative factors can accurately stratify risk for ER and identify patients in whom CRS-HIPEC for CPRM is futile.

Indexed as

Colorectal NeoplasmsHyperthermia, InducedPercutaneous Coronary InterventionPeritoneal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyCytoreduction Surgical ProceduresHumansHyperthermic Intraperitoneal ChemotherapyMedical FutilityNeoplasm Recurrence, LocalRetrospective StudiesSurvival Rate

Identifiers

PMID34224045
PMCPMC8666126
OpenAlexW3179557556

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.